CCR5 antagonists: the answer to inflammatory disease?

Bibliography

• ROSSI D, ZLOTNIK A: The biology of chemokines and their receptors. Annu. Rev. Immunol. (2000) 18:217-242.
   PubMed Web of Science ®Google Scholar
• GERARD C, ROLLINS BJ: Chemokines and disease. Nat. Immunol. (2001) 2(2):108-115.
   PubMed Web of Science ®Google Scholar
• PETKOVIC V, MOGHINI C, PAOLETTI S, UGUCCIONI M, GERBER B: Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role. J. Biol. Chem. (2004) 279(22):23357-23363.
   PubMed Web of Science ®Google Scholar
• RUIZ ME, CICALA C, ARTHOS J et al.: Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV. J. Immunol. (1998) 161(8):4169-4176.
   PubMedGoogle Scholar
• NESS TL, KUNKEL SL, HOGABOAM C: Chemokines: central mediators of the innate response to sepsis. Curr. Immunol. Rev. (2005) 1:237-260.
   Google Scholar
• MOSS RB, MOLL T, EL-KALAY M et al.: TH1/TH2 cells in inflammatory disease states: therapeutic implications. Expert Opin. Biol. Ther. (2004) 4(12):1887-1896.
   PubMed Web of Science ®Google Scholar
• BRUHL H, CIHAK J, STANGASSINGER M, SCHLONDORFF D, MACK M: Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV. J. Immunol. (2001) 166(4):2420-2426.
   PubMedGoogle Scholar
• SAMSON M, LIBERT F, DORANZ BJ et al.: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 382(6593):722-725.
   PubMed Web of Science ®Google Scholar
• SABETI PC, WALSH E, SCHAFFNER SF et al.: The case for selection at CCR5Δ32. PLoS Biol. (2005) 3(11):e378.
   Google Scholar
• GALVANI AP, NOVEMBRE J: The evolutionary history of the CCR5Δ32 HIV-resistance mutation. Microbes Infect. (2005) 7(2):302-309.
   PubMed Web of Science ®Google Scholar
• GLABINSKI AR, TUOHY VK, RANSOHOFF RM: Expression of chemokines RANTES, MIP-1α and GRO-α correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation (1998) 5(3-4):166-171.
   PubMed Web of Science ®Google Scholar
• SELLEBJERG F, MADSEN HO, JENSEN CV, JENSEN J, GARRED P: CCR5δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. (2000) 102(1):98-106.
   PubMedGoogle Scholar
• OPPENHEIM JJ, DONG HF, PLOTZ P et al.: Autoantigens act as tissue-specific chemoattractants. J. Leukoc. Biol. (2005) 77(6):854-861.
   PubMed Web of Science ®Google Scholar
• CRANE IJ, XU H, WALLACE C et al.: Involvement of CCR5 in the passage of TH1-type cells across the blood-retina barrier in experimental autoimmune uveitis. J. Leukoc. Biol. (2005) 79:435-443.
   PubMedGoogle Scholar
• MACK M, BRUHL H, GRUBER R et al.: Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. Arthritis Rheum. (1999) 42(5):981-988.
   PubMed Web of Science ®Google Scholar
• NANKI T, NAGASAKA K, HAYASHIDA K, SAITA Y, MIYASAKA N: Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Immunol. (2001) 167(9):5381-5385.
   PubMed Web of Science ®Google Scholar
• BARNES DA, TSE J, KAUFHOLD M et al.: Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J. Clin. Invest. (1998) 101(12):2910-2919.
   PubMed Web of Science ®Google Scholar
• KUZIEL WA, DAWSON TC, QUINONES M et al.: CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis (2003) 167(1):25-32.
   PubMed Web of Science ®Google Scholar
• BAO L, ZHU Y, ZHU J, LINDGREN JU: Decreased IgG production but increased MIP-1β expression in collagen-induced arthritis in CC chemokine receptor 5-deficient mice. Cytokine (2005) 31(1):64-71.
   PubMedGoogle Scholar
• QUINONES MP, AHUJA SK, JIMENEZ F et al.: Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest. (2004) 113(6):856-866.
   PubMed Web of Science ®Google Scholar
• ZAPICO I, COTO E, RODRIGUEZ A et al.: CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. (2000) 1(4):288-289.
   PubMed Web of Science ®Google Scholar
• PRAHALAD S: Negative association between the chemokine receptor CCR5Δ32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun. (2006) 7(3):264-268.
   PubMed Web of Science ®Google Scholar
• QUINONES MP, ESTRADA CA, KALKONDE Y et al.: The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J. Mol. Med. (2005) 83(9):672-681.
   PubMed Web of Science ®Google Scholar
• PETREK M, CERMAKOVA Z, HUTYROVA B et al.: CC chemokine receptor 5 and IL-1 receptor antagonist gene polymorphisms in patients with primary Sjogren's syndrome. Clin. Exp. Rheumatol. (2002) 20(5):701-703.
   PubMedGoogle Scholar
• SEGERER S, MAC KM, REGELE H, KERJASCHKI D, SCHLONDORFF D: Expression of the CC chemokine receptor 5 in human kidney diseases. Kidney Int. (1999) 56(1):52-64.
   PubMed Web of Science ®Google Scholar
• CHAKRAVORTY SJ, HOWIE AJ, GIRDLESTONE J, GENTLE D, SAVAGE CO: Potential role for monocyte chemotactic protein-4 (MCP-4) in monocyte/macrophage recruitment in acute renal inflammation. J. Pathol. (2001) 194(2):239-246.
   PubMed Web of Science ®Google Scholar
• FISCHEREDER M, LUCKOW B, HOCHER B et al.: CC chemokine receptor 5 and renal-transplant survival. Lancet (2001) 357(9270):1758-1761.
   PubMed Web of Science ®Google Scholar
• GONZALEZ P, ALVAREZ R, BATALLA A et al.: Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. (2001) 2(4):191-195.
   PubMed Web of Science ®Google Scholar
• OHTANI N, OHTANI H, NAKAYAMA T et al.: Infiltration of CD8+ T cells containing RANTES/CCL5+ cytoplasmic granules in actively inflammatory lesions of human chronic gastritis. Lab. Invest. (2004) 84(3):368-375.
   PubMedGoogle Scholar
• ANDRES PG, BECK PL, MIZOGUCHI E et al.: Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated TH2-type immune response in the intestine. J. Immunol. (2000) 164(12):6303-6312.
   PubMed Web of Science ®Google Scholar
• SCHUH JM, BLEASE K, HOGABOAM CM: The role of CC chemokine receptor 5 (CCR5) and RANTES/CCL5 during chronic fungal asthma in mice. Faseb. J. (2002) 16(2):228-230.
   PubMedGoogle Scholar
• PLATT N, HAWORTH R, DARLEY L, GORDON S: The many roles of the class A macrophage scavenger receptor. Int. Rev. Cytol. (2002) 212:1-40.
   PubMedGoogle Scholar
• SRIVASTAVA P, HELMS PJ, STEWART D, MAIN M, RUSSELL G: Association of CCR5Δ32 with reduced risk of childhood but not adult asthma. Thorax (2003) 58(3):222-226.
   PubMed Web of Science ®Google Scholar
• ALKHATIB G, COMBADIERE C, BRODER CC et al.: CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272(5270):1955-1958.
   PubMed Web of Science ®Google Scholar
• RIBEIRO S, HORUK R: The clinical potential of chemokine receptor antagonists. Pharmacol. Ther. (2005) 107(1):44-58.
   PubMed Web of Science ®Google Scholar
• MOENCH C, UHRIG A, LOHSE AW, OTTO G: CC chemokine receptor 5δ32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl. (2004) 10(3):434-439.
   PubMedGoogle Scholar
• MORENO C, GUSTOT T, NICAISE C et al.: CCR5 deficiency exacerbates T cell-mediated hepatitis in mice. Hepatology (2005) 42(4):854-862.
   PubMed Web of Science ®Google Scholar
• ERI R, JONSSON JR, PANDEYA N et al.: CCR5Δ32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun (2004) 5(6):444-450.
   PubMed Web of Science ®Google Scholar
• WOITAS RP, AHLENSTIEL G, IWAN A et al.: Frequency of the HIV-protective CC chemokine receptor 5-Δ32/Δ32 genotype is increased in hepatitis C. Gastroenterology (2002) 122(7):1721-1728.
   PubMed Web of Science ®Google Scholar
• WALD O, PAPPO O, ARI ZB et al.: The CCR5Δ32 allele is associated with reduced liver inflammation in hepatitis C virus infection. Eur. J. Immunogenet. (2004) 31(6):249-252.
   PubMedGoogle Scholar
• ZHANG M, GOEDERT JJ, O'BRIEN TR: High frequency of CCR5δ32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1. Gastroenterology (2003) 124(3):867-868.
   PubMed Web of Science ®Google Scholar
• HELLIER S, FRODSHAM AJ, HENNIG BJ et al.: Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology (2003) 38(6):1468-1476.
   PubMed Web of Science ®Google Scholar
• GLASS WG, LIM JK, CHOLERA R et al.: Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. (2005) 202(8):1087-1098.
   PubMed Web of Science ®Google Scholar
• GLASS WG, MCDERMOTT DH, LIM JK et al.: CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. (2006) 203(1):35-40.
   PubMed Web of Science ®Google Scholar
• SAITA Y, KONDO M, MIYAZAKI T, YAMAJI N, SHIMIZU Y: Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists. Eur. J. Pharmacol. (2005) 518(2-3):227-233.
   PubMedGoogle Scholar
• SCHUH JM, BLEASE K, BRUHL H, MACK M, HOGABOAM CM: Intrapulmonary targeting of RANTES/CCL5-responsive cells prevents chronic fungal asthma. Eur. J. Immunol. (2003) 33(11):3080-3090.
   PubMed Web of Science ®Google Scholar
• PROUDFOOT AE, HANDEL TM, JOHNSON Z et al.: Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. USA. (2003) 100(4):1885-1890.
   PubMed Web of Science ®Google Scholar
• HANDEL TM, JOHNSON Z, CROWN SE, LAU EK, PROUDFOOT AE: Regulation of protein function by glycosaminoglycans – as exemplified by chemokines. Annu. Rev. Biochem. (2005) 74:385-410.
   PubMed Web of Science ®Google Scholar
• PROUDFOOT AE, POWER CA, HOOGEWERF AJ et al.: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. (1996) 271(5):2599-2603.
   PubMed Web of Science ®Google Scholar
• MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. (1998) 187(8):1215-1224.
   PubMed Web of Science ®Google Scholar
• SHAHRARA S, PROUDFOOT AE, WOODS JM et al.: Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum. (2005) 52(6):1907-1919.
   PubMed Web of Science ®Google Scholar
• PLATER-ZYBERK C, HOOGEWERF AJ, PROUDFOOT AE, POWER CA, WELLS TN: Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol. Lett. (1997) 57(1-3):117-120.
   PubMed Web of Science ®Google Scholar
• STUMBLES PA, STRICKLAND DH, PIMM CL et al.: Regulation of dendritic cell recruitment into resting and inflamed airway epithelium: use of alternative chemokine receptors as a function of inducing stimulus. J. Immunol. (2001) 167(1):228-234.
   PubMedGoogle Scholar
• VEILLARD NR, KWAK B, PELLI G et al.: Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res. (2004) 94(2):253-261.
   PubMed Web of Science ®Google Scholar
• MARINO AP, DA SILVA A, DOS SANTOS P et al.: Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis. Circulation (2004) 110(11):1443-1449.
   PubMed Web of Science ®Google Scholar
• YUN JJ, WHITING D, FISCHBEIN MP et al.: Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation (2004) 109(7):932-937.
   PubMed Web of Science ®Google Scholar
• DIEDRICHS-MOHRING M, NELSON PJ, PROUDFOOT AE, THURAU SR, WILDNER G: The effect of the CC chemokine receptor antagonist Met-RANTES on experimental autoimmune uveitis and oral tolerance. J. Neuroimmunol. (2005) 164(1-2):22-30.
   PubMedGoogle Scholar
• AJUEBOR MN, HOGABOAM CM, KUNKEL SL, PROUDFOOT AE, WALLACE JL: The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J. Immunol. (2001) 166(1):552-558.
   PubMed Web of Science ®Google Scholar
• MATSUI M, WEAVER J, PROUDFOOT AE et al.: Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J. Neuroimmunol. (2002) 128(1-2):16-22.
   PubMed Web of Science ®Google Scholar
• BHATIA M, PROUDFOOT AE, WELLS TN et al.: Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis. Br. J. Surg. (2003) 90(6):698-704.
   PubMedGoogle Scholar
• PASTORE C, PICCHIO GR, GALIMI F et al.: Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob. Agents Chemother. (2003) 47(2):509-517.
   PubMedGoogle Scholar
• ELSNER J, MACK M, BRUHL H et al.: Differential activation of CC chemokine receptors by AOP-RANTES. J. Biol. Chem. (2000) 275(11):7787-7794.
   PubMed Web of Science ®Google Scholar
• PROUDFOOT AE, BUSER R, BORLAT F et al.: Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J. Biol. Chem. (1999) 274(45):32478-32485.
   PubMed Web of Science ®Google Scholar
• OPPERMANN M, MACK M, PROUDFOOT AE, OLBRICH H: Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. J. Biol. Chem. (1999) 274(13):8875-8885.
   PubMedGoogle Scholar
• SIGNORET N, PELCHEN-MATTHEWS A, MACK M, PROUDFOOT AE, MARSH M: Endocytosis and recycling of the HIV coreceptor CCR5. J. Cell Biol. (2000) 151(6):1281-1294.
   PubMedGoogle Scholar
• SIMMONS G, CLAPHAM PR, PICARD L et al.: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 276(5310):276-279.
   PubMed Web of Science ®Google Scholar
• ANDERS HJ, FRINK M, LINDE Y et al.: CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J. Immunol. (2003) 170(11):5658-5666.
   PubMedGoogle Scholar
• SABBE R, PICCHIO GR, PASTORE C et al.: Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J. Virol. (2001) 75(2):661-671.
   PubMed Web of Science ®Google Scholar
• JOHNSON Z, KOSCO-VILBOIS MH, HERREN S et al.: Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Immunol. (2004) 173(9):5776-5785.
   PubMed Web of Science ®Google Scholar
• BABA M, NISHIMURA O, KANZAKI N et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA (1999) 96(10):5698-5703.
   PubMed Web of Science ®Google Scholar
• DRAGIC T, TRKOLA A, THOMPSON DA et al.: A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA (2000) 97(10):5639-5644.
   PubMed Web of Science ®Google Scholar
• TAKAMI S, MINAMI M, KATAYAMA T et al.: TAK-779, a nonpeptide CC chemokine receptor antagonist, protects the brain against focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. (2002) 22(7):780-784.
   PubMed Web of Science ®Google Scholar
• TOKUYAMA H, UEHA S, KURACHI M et al.: The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int. Immunol. (2005) 17(8):1023-1034.
   PubMed Web of Science ®Google Scholar
• YANG YF, MUKAI T, GAO P et al.: A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur. J. Immunol. (2002) 32(8):2124-2132.
   PubMed Web of Science ®Google Scholar
• GAO P, ZHOU XY, YASHIRO-OHTANI Y et al.: The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two TH1 chemokine receptors CCR5 and CXCR3. J. Leukoc. Biol. (2003) 73(2):273-280.
   PubMed Web of Science ®Google Scholar
• ARAMAKI Y, SETO M, OKAWA T et al.: Synthesis of 1-benzothiepine and 1-benzazepine derivatives as orally active CCR5 antagonists. Chem. Pharm. Bull. (Tokyo) (2004) 52(2):254-258.
   PubMedGoogle Scholar
• BABA M, TAKASHIMA K, MIYAKE H et al.: TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. (2005) 49(11):4584-4591.
   PubMed Web of Science ®Google Scholar
• TAKASHIMA K, MIYAKE H, KANZAKI N et al.: Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob. Agents Chemother. (2005) 49(8):3474-3482.
   PubMed Web of Science ®Google Scholar
• STRIZKI JM, XU S, WAGNER NE et al.: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA (2001) 98(22):12718-12723.
   PubMed Web of Science ®Google Scholar
• TAGAT JR, MCCOMBIE SW, NAZARENO D et al.: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrim idinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4- (trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperaz inyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. (2004) 47(10):2405-2408.
   PubMed Web of Science ®Google Scholar
• FINLAYSON K, WITCHEL HJ, MCCULLOCH J, SHARKEY J: Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol. (2004) 500(1-3):129-142.
   PubMed Web of Science ®Google Scholar
• TAGAT JR, MCCOMBIE SW, STEENSMA RW et al.: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett (2001) 11(16):2143-2146.
   PubMed Web of Science ®Google Scholar
• MCCOMBIE SW, TAGAT JR, VICE SF et al.: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. Bioorg. Med. Chem. Lett (2003) 13(3):567-571.
   PubMed Web of Science ®Google Scholar
• STRIZKI JM, TREMBLAY C, XU S et al.: Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (2005) 49(12):4911-4919.
   PubMed Web of Science ®Google Scholar
• GREAVES W, LANDOVITZ R, FATKENHEUER G et al.: Late virologic breakthrough in treatment-naive patients on a regimen of combivir + vicriviroc. 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, USA (2006):Abstract.
   Google Scholar
• VIERBOOM MP, ZAVODNY PJ, CHOU CC et al.: Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum. (2005) 52(2):627-636.
   PubMed Web of Science ®Google Scholar
• WALKER DK, ABEL S, COMBY P et al.: Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. (2005) 33(4):587-595.
   PubMed Web of Science ®Google Scholar
• FATKENHEUER G, POZNIAK AL, JOHNSON MA et al.: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. (2005) 11(11):1170-1172.
   PubMed Web of Science ®Google Scholar
• MAEDA K, YOSHIMURA K, SHIBAYAMA S et al.: Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. (2001) 276(37):35194-35200.
   PubMed Web of Science ®Google Scholar
• MAEDA K, NAKATA H, KOH Y et al.: Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. (2004) 78(16):8654-8662.
   PubMed Web of Science ®Google Scholar
• HALE JJ, BUDHU RJ, MILLS SG et al.: 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg. Med. Chem. Lett. (2001) 11(11):1437-1440.
   PubMed Web of Science ®Google Scholar
• HALE JJ, BUDHU RJ, HOLSON EB et al.: 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. Bioorg. Med. Chem. Lett. (2001) 11(20):2741-2745.
   PubMed Web of Science ®Google Scholar
• FINKE PE, MEURER LC, OATES B et al.: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N- (phenylsulfonyl)amino]-4-(piperidin-1-yl) butanes. Bioorg. Med. Chem. Lett. (2001) 11(2):265-270.
   PubMed Web of Science ®Google Scholar
• FINKE PE, MEURER LC, OATES B et al.: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)- N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes. Bioorg. Med. Chem. Lett. (2001) 11(18):2469-2473.
   PubMed Web of Science ®Google Scholar
• FINKE PE, OATES B, MILLS SG et al.: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure–activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzy loxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. (2001) 11(18):2475-2479.
   PubMed Web of Science ®Google Scholar
• BURROWS JN, CUMMING JG, FILLERY SM et al.: Modulators of the human CCR5 receptor. Part 1: discovery and initial SAR of 1-(3,3-diphenyl propyl)-piperidinyl amides and ureas. Bioorg. Med. Chem. Lett (2005) 15(1):25-28.
   PubMed Web of Science ®Google Scholar
• HOWARD OM, KORTE T, TARASOVA NI et al.: Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J. Leukoc. Biol. (1998) 64(1):6-13.
   PubMed Web of Science ®Google Scholar
• THOMA G, NUNINGER F, SCHAEFER M et al.: Orally bioavailable competitive CCR5 antagonists. J. Med. Chem. (2004) 47(8):1939-1955.
   PubMed Web of Science ®Google Scholar
• VEAZEY RS, KLASSE PJ, SCHADER SM et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 438(7064):99-102.
   PubMed Web of Science ®Google Scholar
• VEAZEY RS, SPRINGER MS, MARX PA et al.: Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med (2005) 11(12):1293-1294.
   PubMed Web of Science ®Google Scholar